AstraZeneca PLC (LON:AZN) Insider Buys £190,200 in Stock

AstraZeneca PLC (LON:AZN) insider Tony Mok bought 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of £126.80 ($159.64) per share, for a total transaction of £190,200 ($239,456.12).

AstraZeneca Stock Up 0.9 %

Shares of LON AZN opened at £100.62 ($126.68) on Friday. The company’s 50 day moving average price is £113.96 and its 200-day moving average price is £120.77. The company has a market capitalization of £155.96 billion, a P/E ratio of 3,194.29, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca PLC has a 52-week low of GBX 9,461 ($119.11) and a 52-week high of £133.88 ($168.55).

Wall Street Analyst Weigh In

Several research firms have commented on AZN. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($138.49) target price on shares of AstraZeneca in a report on Tuesday, September 3rd. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank reiterated a “buy” rating and set a £150 ($188.85) target price on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($176.26) target price on shares of AstraZeneca in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of £104.12 ($131.09).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.